CA2368784A1 - Methods of treating clinical diseases with isoflavones - Google Patents

Methods of treating clinical diseases with isoflavones Download PDF

Info

Publication number
CA2368784A1
CA2368784A1 CA002368784A CA2368784A CA2368784A1 CA 2368784 A1 CA2368784 A1 CA 2368784A1 CA 002368784 A CA002368784 A CA 002368784A CA 2368784 A CA2368784 A CA 2368784A CA 2368784 A1 CA2368784 A1 CA 2368784A1
Authority
CA
Canada
Prior art keywords
soy protein
diet
isoflavone
soy
isoflavones
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002368784A
Other languages
English (en)
French (fr)
Inventor
William J. Banz
Michael R. Peluso
Todd A. Winters
Michael F. Shanahan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Southern Illinois University Carbondale
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2368784A1 publication Critical patent/CA2368784A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Botany (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002368784A 1999-04-20 2000-04-20 Methods of treating clinical diseases with isoflavones Abandoned CA2368784A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13015699P 1999-04-20 1999-04-20
US60/130,156 1999-04-20
PCT/US2000/010543 WO2000062774A1 (en) 1999-04-20 2000-04-20 Methods of treating clinical diseases with isoflavones

Publications (1)

Publication Number Publication Date
CA2368784A1 true CA2368784A1 (en) 2000-10-26

Family

ID=22443325

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002368784A Abandoned CA2368784A1 (en) 1999-04-20 2000-04-20 Methods of treating clinical diseases with isoflavones

Country Status (6)

Country Link
US (2) US6592910B1 (enExample)
EP (1) EP1171119A1 (enExample)
JP (1) JP2002542192A (enExample)
AU (1) AU777254B2 (enExample)
CA (1) CA2368784A1 (enExample)
WO (1) WO2000062774A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6261565B1 (en) * 1996-03-13 2001-07-17 Archer Daniels Midland Company Method of preparing and using isoflavones
AU3228100A (en) * 1999-02-10 2000-08-29 Eastman Chemical Company Corn fiber for the production of advanced chemicals and materials
JP2002542192A (ja) * 1999-04-20 2002-12-10 ボード オブ トラスティース， サザン イリノイ ユニバーシティ イソフラボンで臨床的な疾患を処置する方法
JP4970690B2 (ja) 2000-04-14 2012-07-11 マース インコーポレーテッド 血管の健康状態を改善するための組成物および方法
WO2002087567A2 (en) * 2001-05-02 2002-11-07 Kgk Synergize Inc. Polymethoxylated flavones for treating insulin resistance
US6596762B2 (en) 2001-05-17 2003-07-22 The Regents Of The University Of Colorado Antioxidant compositions and use for treatment of hepatic steatosis and steatohepatitis
JP2012149096A (ja) * 2001-12-18 2012-08-09 Daicho Kikaku:Kk 抗炎症剤
JP5384777B2 (ja) * 2001-12-18 2014-01-08 有限会社大長企画 強筋肉剤、抗炎症剤
WO2003094627A1 (en) * 2002-05-07 2003-11-20 Solae, Llc Low isoflavones, high saponins soy protein product and process for producing the same
US20030232068A1 (en) * 2002-06-14 2003-12-18 Lewandowski Daniel J. Food product having increased bile acid binding capacity
CN1681386B (zh) 2002-07-24 2010-05-26 儿童医院医疗中心 含有对映体牛尿酚的组合物和产物及其制备方法
US8668914B2 (en) 2002-07-24 2014-03-11 Brigham Young University Use of equol for treating skin diseases
AU2003255232A1 (en) * 2002-08-07 2004-02-25 University Of Mississippi Antigiardial agents and use thereof
AU2003286781B2 (en) 2002-10-29 2009-05-21 Brigham Young University Use of equol for treating androgen mediated diseases
US8580846B2 (en) 2002-10-29 2013-11-12 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
FR2861303A1 (fr) * 2003-10-24 2005-04-29 Sanofi Synthelabo Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
JP2008514198A (ja) * 2004-09-27 2008-05-08 カーギル インコーポレイテッド シクロデキストリン包接複合体及びその製造方法
JP2008214191A (ja) * 2005-04-27 2008-09-18 Toyo Shinyaku:Kk 肝中脂質蓄積抑制剤
US20090214446A1 (en) * 2005-06-13 2009-08-27 Cargill, Incorporated Cyclodextrin inclusion complexes and methods of preparing same
AU2006259877A1 (en) * 2005-06-13 2006-12-28 Cargill, Incorporated Cyclodextrin inclusion complexes and methods of preparing same
US20090185985A1 (en) * 2006-06-13 2009-07-23 Cargill, Incorporated Large-particle cyclodextrin inclusion complexes and methods of preparing same
MX2009007084A (es) * 2006-12-27 2009-08-20 Cargill Inc Complejos de inclusion de ciclodextrina y metodos para preparar los mismos.
US20080283693A1 (en) * 2007-05-15 2008-11-20 Evans Michael J F Propulsion apparatus and system
US20090176871A1 (en) * 2008-01-07 2009-07-09 Schoenwetter Phillip E Treatments for Domestic Animals Having Sex Hormone Deficiencies Using Soy Germ Isoflavones
KR20110138001A (ko) * 2010-06-18 2011-12-26 (주)아모레퍼시픽 유색콩 추출물을 함유하는 조성물
KR20110138000A (ko) * 2010-06-18 2011-12-26 (주)아모레퍼시픽 유색콩 추출물을 함유하는 조성물
BR112013026896A8 (pt) * 2011-04-20 2018-01-16 Nestec Sa métodos e composições adequadas para prevenir e tratar hiperleptinemia
US8658787B2 (en) 2011-09-16 2014-02-25 Galectin Therapeutics Inc. Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
WO2013184892A1 (en) 2012-06-06 2013-12-12 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase
US9132117B2 (en) 2013-06-17 2015-09-15 Kgk Synergize, Inc Compositions and methods for glycemic control of subjects with impaired fasting glucose
KR102010505B1 (ko) * 2014-11-18 2019-08-14 경북대학교 산학협력단 페놀 화합물을 유효성분으로 포함하는 항혈전용 조성물
BR112017028194B1 (pt) 2015-07-10 2023-03-14 Ionis Pharmaceuticals, Inc Composto oligomérico modulador de diaciglicerol aciltransferase 2 (dgat2), composição, e seus usos
US20210128520A1 (en) * 2017-07-24 2021-05-06 Ke Jim Neuroprotective isoflavone compositions and methods
CN110141565A (zh) * 2019-05-10 2019-08-20 丽水市中心医院 芒柄花黄素在制备治疗肺动脉高压药物中的应用及治疗肺动脉高压药物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1459421A (en) * 1973-02-03 1976-12-22 British Arkady Co Ltd Production of foodstuffs from whey and soya
JPS54117034A (en) * 1978-02-28 1979-09-11 Nippon Shoji Kk Treating agent for consciousness and perception motion disorder
DE3040246C2 (de) * 1979-10-29 1985-01-10 Osaka Chemical Laboratory Co., Ltd., Osaka Sojasaponine A↓1↓ und A↓2↓ und ihre Verwendung
JPS5933232A (ja) * 1982-08-19 1984-02-23 Tokiwa Kanpou Seiyaku:Kk マメ科植物からサポニン類およびフラボン類の分離方法
US4557927A (en) * 1983-03-10 1985-12-10 Kabushiki Kaisha Hoyashibara Food products and process for producing same
JPS6269960A (ja) * 1985-09-21 1987-03-31 Kibun Kk 豆乳の製造法
JPH0714927B2 (ja) * 1988-04-06 1995-02-22 キッコーマン株式会社 イソフラボン化合物の製造法
EP1477178A3 (en) * 1992-05-19 2005-02-16 KELLY, Graham Edmund Health supplements containing phyto-oestrogens, analogues or metabolites thereof
US5885632A (en) * 1993-12-14 1999-03-23 Nichimo Co., Ltd. Process for preparing a product from a pulse crop as a starting material and a food containing the product prepared from a pulse crop as a starting material
CN1123115A (zh) * 1994-11-16 1996-05-29 邮电部干部学校威普健饮料有限公司 一种磷脂饮料及其制备方法
US6261565B1 (en) * 1996-03-13 2001-07-17 Archer Daniels Midland Company Method of preparing and using isoflavones
JPH09255570A (ja) * 1996-03-21 1997-09-30 Fujitsuko Kk 血中脂質濃度を低減させる薬剤及び可食性組成物
WO1997037549A1 (en) * 1996-04-10 1997-10-16 Nichimo Co., Ltd. Substance containing health-promoting component and process for the production thereof
WO1998003084A1 (en) * 1996-07-18 1998-01-29 Nutricor, Inc. Nutritious food preparations and methods for making them
JP2829388B2 (ja) * 1996-09-27 1998-11-25 農林水産省四国農業試験場長 脂肪細胞への細胞分化促進用組成物
CA2280093A1 (en) * 1997-02-04 1998-08-06 John V. Kosbab Compositions and methods for prevention and treatment of vascular degenerative diseases
US5855892A (en) 1997-09-19 1999-01-05 Potter; Susan M. Method for decreasing LDL-cholesterol concentration and increasing HDL-cholesterol concentration in the blood to reduce the risk of atherosclerosis and vascular disease
US6132795A (en) * 1998-03-15 2000-10-17 Protein Technologies International, Inc. Vegetable protein composition containing an isoflavone depleted vegetable protein material with an isoflavone containing material
BR9915693A (pt) 1998-11-25 2001-08-14 Nutri Pharma As Composição compreendendo proteìna de soja, fibra de dieta e um composto fitoestrogênio e seu uso na prevenção e/ou tratamento de diabetes tipo 2, a sìdrome metabólica e doenças cardiovasculares associadas
AU1404600A (en) 1998-11-25 2000-06-13 Nutri Pharma Asa Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of pulmonary diseases
ATE253925T1 (de) 1998-11-25 2003-11-15 Nutri Pharma As Zusammensetzung enthaltend sojaprotein, diätfasern und phytoestrogen sowie ihre verwendung zur vorbeugung und/oder behandlung von kardiovaskulären erkrankungen
US20030113390A1 (en) * 1998-11-25 2003-06-19 Hoie Lars Henrik Composition comprising soy protein, dietary fibers and a phytoestrogen compound and use thereof in the prevention and/or treatment of various diseases
US6180139B1 (en) * 1998-12-04 2001-01-30 Viva America Marketing, Inc. Composition and method for treating nonalcoholic steatohepatitis
JP2002542192A (ja) * 1999-04-20 2002-12-10 ボード オブ トラスティース， サザン イリノイ ユニバーシティ イソフラボンで臨床的な疾患を処置する方法
US6664287B2 (en) * 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
EP1361870A2 (en) * 2001-02-01 2003-11-19 Nutri Pharma ASA A substance for use in a dietary supplement or for the preparation of a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome

Also Published As

Publication number Publication date
AU4471300A (en) 2000-11-02
AU777254B2 (en) 2004-10-07
US20030180404A1 (en) 2003-09-25
US6592910B1 (en) 2003-07-15
JP2002542192A (ja) 2002-12-10
WO2000062774A1 (en) 2000-10-26
EP1171119A1 (en) 2002-01-16

Similar Documents

Publication Publication Date Title
US6592910B1 (en) Methods of treating clinical diseases with isoflavones
US6572876B2 (en) Administering a composition containing plant sterol, soy protein and isoflavone for reducing LDL-cholesterol
US5855892A (en) Method for decreasing LDL-cholesterol concentration and increasing HDL-cholesterol concentration in the blood to reduce the risk of atherosclerosis and vascular disease
US5952374A (en) Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function
Haraguchi et al. Protection against oxidative damage by dihydroflavonols in Engelhardtia chrysolepis
DE69231672T2 (de) Verfahren für die hemmung von aldh-i bei behandlung von alkoholabhaengigkeit oder alkoholmissbrauch
CA2352005C (en) Extracts, compounds & pharmaceutical compositions having anti-diabetic activity and their use
US6326366B1 (en) Hormone replacement therapy
US6375994B1 (en) Preparation of fiber, L-glutamine and a soy derivative for the purpose of enhancement of isoflavone bioavailability
Fang et al. Effect of genistein supplementation on tissue genistein and lipid peroxidation of serum, liver and low-density lipoprotein in hamsters
WO1995000158A1 (en) Dietary supplement incorporating beta-sitosterol and pectin
US7285297B1 (en) Method of reducing low density liproprotein cholesterol concentration
Majak Mammalian metabolism of toxic glycosides from plants
Martini Extrahepatic manifestations of cirrhosis
WO1997035598A1 (en) Pharmaceutical compositions and methods for the manufacture thereof
US20060154855A1 (en) Methods and compositions for beta conglycinin fraction of soy protein
Ishiguro et al. Effects of calmodulin inhibitors on amylase secretion from rat pancreatic acini
Lichtenstein Soy protein, isoflavonoids, and risk of developing coronary heart disease
US4789670A (en) Method and compositions for suppression of atherogenesis utilizing cholesterol hydroperoxides
AU783838B2 (en) Composition for and method of reducing low density lipoprotein cholesterol concentration
AU779014B2 (en) Composition for and method of reducing low density lipoprotein cholesterol concentration
JPWO2006035897A1 (ja) 性ホルモン結合グロブリン阻害組成物

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued